Edition:
United Kingdom

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

5,530JPY
21 Feb 2018
Change (% chg)

¥-47 (-0.84%)
Prev Close
¥5,577
Open
¥5,540
Day's High
¥5,560
Day's Low
¥5,494
Volume
1,197,500
Avg. Vol
1,360,715
52-wk High
¥6,465
52-wk Low
¥5,396

Latest Key Developments (Source: Significant Developments)

R&I affirms Shionogi & Co Ltd's rating at "A+" and says stable outlook-R&I
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Shionogi & Co Ltd <4507.T> ::Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I.Rating outlook stable -R&I.  Full Article

Shionogi to repurchase shares and retire treasury shares
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Shionogi & Co Ltd <4507.T>:Says it will repurchase up to 4.8 million shares, representing 1.5 percent of outstanding.Says share repurchase price at up to 30 billion yen in total.Says repurchase period from Dec. 1 to Feb. 28, 2018.Says it will retire 5 million shares of its common stock on March 12, 2018 .  Full Article

UMN Pharma says business and capital alliance with Shionogi
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - UMN Pharma Inc <4585.T>:Says it signed business and capital alliance agreement with Shionogi & Co Ltd <<<4507.T>>> on Oct. 31 .Says two entities will mainly cooperate on establishment of technological basis for drug discovery related to preventive vaccines against infectious diseases .Says it will issue 600,000 shares and first series convertible bonds with subscription warrants to Shionogi & Co Ltd, to raise 1.64 billion yen in total .Payment date on Nov. 16 .  Full Article

Shionogi and Purdue Pharma announce U.S availability of Symproic (naldemedine)
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Shionogi & Co Ltd <4507.T>::Shionogi inc - co, Purdue Pharma L.P. announce that Symproic (naldemedine) 0.2 mg tablets are now available throughout United States​.Shionogi - FDA ‍approved Symproic as once-daily oral tablet for treatment of opioid-induced constipation in adult patients with chronic non-cancer pain​.  Full Article

PeptiDream to set up Osaka-based special peptide drugs JV
Monday, 7 Aug 2017 

Aug 7 (Reuters) - PeptiDream Inc <4587.T>:Says it plans to set up Osaka-based joint venture with Shionogi & Co., Ltd <<<4507.T>>> and Sekisui Chemical Co., Ltd. <<<4204.T>>>, on Sept. 1.Says the joint venture will be engaged in R&D, production and sales of special peptide drugs.  Full Article

Shionogi & Co says sales transfer of 21 product and tansfer of manufacturing and marketing approval
Tuesday, 2 Aug 2016 

Shionogi & Co Ltd <4507.T>: Says it to transfer sale of 21 products on Dec. 1 and manufacturing and marketing approval after 2017 to Kyowa Pharmaceutical Industry Co., Ltd. .Says Kyowa Pharmaceutical Industry Co., Ltd. to pay 15.4 billion yen to the co on Dec. 1 for the sales transfer of 21 products.  Full Article

Lupin buys Japan's Shionogi's product portfolio<4507.T>
Tuesday, 2 Aug 2016 

Lupin Ltd : Acquires branded product portfolio from Shionogi in Japan . To acquire 21 long-listed products from Shionogi & Co .  Full Article

Shionogi and Astellas Pharma looking to sell drug brands that have lost patent protection - Nikkei<4503.T><4507.T>
Monday, 4 Jul 2016 

Nikkei: Shionogi and Astellas Pharma are looking to sell off drug brands that have lost patent protection - Nikkei . Shionogi could select buyers at the end of July; proceeds from the sales estimated at nearly 20 billion yen - Nikkei . Astellas could receive up to 50 billion yen by divesting several drugs - Nikkei .  Full Article

Shionogi & Co Ltd adjusts conversion price of 2019 due Euro Yen - denominated convertible bonds with warrants to 4,167.5 yen
Thursday, 23 Jun 2016 

Shionogi & Co Ltd <4507.T>:Says it adjusts conversion price of 2019 due Euro Yen - denominated convertible bonds with warrants to 4,167.5 yen from 4,177.6 yen, effective from April 1.  Full Article

ViiV Healthcare says FDA approves sNDA for dolutegravir
Friday, 10 Jun 2016 

Viiv Healthcare Ltd : ViiV Healthcare announces FDA approval to lower weight limit for dolutegravir in children and adolescents living with HIV . FDA has approved a supplemental new drug application for dolutegravir 10mg and 25mg oral tablets, reducing weight limit . FDA approved supplemental new drug application for dolutegravir oral tablets, reducing weight limit to at least 30kg Further company coverage: [IPO-VIHL.L] (Bengaluru Newsroom: +91 80 6749 1136).  Full Article

BRIEF-Shionogi says ViiV Healthcare files patent infringement litigation against Gilead Sciences over bictegravir

* Says it announced that ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has filed patent infringement litigation against Gilead Sciences Inc. over bictegravir in the United States and Canada